Lead Egg Quality Therapeutic
Improvement of egg quality / reduction of meiotic aneuploidy in women aged 33+ undergoing IVF
Pre-clinicalActive
Key Facts
Indication
Improvement of egg quality / reduction of meiotic aneuploidy in women aged 33+ undergoing IVF
Phase
Pre-clinical
Status
Active
Company
About U-Ploid
U-Ploid is a private, pre-clinical stage biotech founded in 2018 in Cambridge, UK, targeting the age-related infertility crisis. The company's lead program is a therapeutic designed to reduce chromosomal errors (meiotic aneuploidy) in eggs, which is the primary cause of IVF failure in women over 33. By improving egg quality, U-Ploid seeks to significantly increase IVF success rates for older women, addressing a major unmet need in reproductive medicine with a scalable treatment compatible with current clinical workflows.
View full company profile